ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KTTA Pasithea Therapeutics Corporation

5.2837
0.0237 (0.45%)
Last Updated: 17:20:33
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pasithea Therapeutics Corporation NASDAQ:KTTA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0237 0.45% 5.2837 5.25 5.31 5.38 5.26 5.38 1,651 17:20:33

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

07/09/2023 9:14pm

GlobeNewswire Inc.


Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Pasithea Therapeutics Charts.

Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.

Attendees interested in 1 x 1 meetings are invited to request them through the conference’s meeting scheduler at meetings@hcwco.com or by calling or emailing the company contact below.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Company Contact Patrick GaynesCorporate Communicationspgaynes@pasithea.com+1 (310) 989-5666

1 Year Pasithea Therapeutics Chart

1 Year Pasithea Therapeutics Chart

1 Month Pasithea Therapeutics Chart

1 Month Pasithea Therapeutics Chart

Your Recent History

Delayed Upgrade Clock